ATE240733T1 - Kombination von 5-ht wiederaufnahme-inhibitoren und h5-ht 1b antagonisten oder partiellen agonisten - Google Patents

Kombination von 5-ht wiederaufnahme-inhibitoren und h5-ht 1b antagonisten oder partiellen agonisten

Info

Publication number
ATE240733T1
ATE240733T1 AT98944375T AT98944375T ATE240733T1 AT E240733 T1 ATE240733 T1 AT E240733T1 AT 98944375 T AT98944375 T AT 98944375T AT 98944375 T AT98944375 T AT 98944375T AT E240733 T1 ATE240733 T1 AT E240733T1
Authority
AT
Austria
Prior art keywords
rupup
antagonists
inhibitors
combination
partial agonists
Prior art date
Application number
AT98944375T
Other languages
German (de)
English (en)
Inventor
Stefan Berg
Svante Ross
Seth-Olov Thorberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE240733T1 publication Critical patent/ATE240733T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Replacement Of Web Rolls (AREA)
  • Winding, Rewinding, Material Storage Devices (AREA)
AT98944375T 1997-09-18 1998-09-09 Kombination von 5-ht wiederaufnahme-inhibitoren und h5-ht 1b antagonisten oder partiellen agonisten ATE240733T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703375A SE9703375D0 (sv) 1997-09-18 1997-09-18 A new combination
PCT/SE1998/001601 WO1999013877A1 (fr) 1997-09-18 1998-09-09 Combinaison d'un inhibiteur de recaptage 5-ht et un antagoniste de h5-ht1b ou agoniste partiel

Publications (1)

Publication Number Publication Date
ATE240733T1 true ATE240733T1 (de) 2003-06-15

Family

ID=20408295

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98944375T ATE240733T1 (de) 1997-09-18 1998-09-09 Kombination von 5-ht wiederaufnahme-inhibitoren und h5-ht 1b antagonisten oder partiellen agonisten

Country Status (29)

Country Link
US (1) US6159971A (fr)
EP (1) EP1014985B1 (fr)
JP (1) JP2001516718A (fr)
KR (1) KR20010024076A (fr)
CN (1) CN1195519C (fr)
AR (1) AR015448A1 (fr)
AT (1) ATE240733T1 (fr)
AU (1) AU752722B2 (fr)
BR (1) BR9812088A (fr)
CA (1) CA2302382A1 (fr)
DE (1) DE69814882T2 (fr)
DK (1) DK1014985T3 (fr)
EE (1) EE04141B1 (fr)
ES (1) ES2200370T3 (fr)
HU (1) HUP0200602A3 (fr)
IL (1) IL134776A0 (fr)
IS (1) IS5406A (fr)
MY (1) MY116280A (fr)
NO (1) NO20001399L (fr)
NZ (1) NZ503171A (fr)
PL (1) PL339371A1 (fr)
PT (1) PT1014985E (fr)
RU (1) RU2214824C2 (fr)
SE (1) SE9703375D0 (fr)
SK (1) SK2852000A3 (fr)
TR (1) TR200000727T2 (fr)
TW (1) TW589183B (fr)
WO (1) WO1999013877A1 (fr)
ZA (1) ZA987817B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
WO2002087566A1 (fr) * 2001-05-01 2002-11-07 H. Lundbeck A/S Utilisation d'escitalopram pur enantiomere
ES2323451T7 (es) * 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
AR047553A1 (es) 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
KR100511288B1 (ko) * 2003-11-14 2005-08-31 엘지전자 주식회사 4대의 압축기를 구비한 공기조화기의 실외기
WO2006091725A1 (fr) * 2005-02-23 2006-08-31 The Silvan S. Tomkins Institute Traitement de l'anhedonie
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
FR2890862B1 (fr) * 2005-09-19 2008-01-25 Sanofi Aventis Sa Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
CA2626134C (fr) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Derives de benzimidazolone utiles pour le traitement des troubles premenstruels et d'autres troubles sexuels chez la femme
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
EP2037927B1 (fr) 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibansérine dans le traitement de l'incontinence urinaire et des maladies associées
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090045945A (ko) 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT533268E (pt) * 1991-09-18 2002-02-28 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9703374D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination

Also Published As

Publication number Publication date
DK1014985T3 (da) 2003-09-15
IS5406A (is) 2000-03-15
PL339371A1 (en) 2000-12-18
US6159971A (en) 2000-12-12
NO20001399L (no) 2000-05-10
CN1195519C (zh) 2005-04-06
SK2852000A3 (en) 2000-09-12
AU9193098A (en) 1999-04-05
EP1014985B1 (fr) 2003-05-21
ES2200370T3 (es) 2004-03-01
CN1278729A (zh) 2001-01-03
IL134776A0 (en) 2001-04-30
CA2302382A1 (fr) 1999-03-25
WO1999013877A1 (fr) 1999-03-25
EP1014985A1 (fr) 2000-07-05
PT1014985E (pt) 2003-10-31
TR200000727T2 (tr) 2000-09-21
HUP0200602A3 (en) 2003-04-28
KR20010024076A (ko) 2001-03-26
DE69814882D1 (de) 2003-06-26
NZ503171A (en) 2002-02-01
EE200000141A (et) 2001-02-15
EE04141B1 (et) 2003-10-15
AU752722B2 (en) 2002-09-26
HK1032739A1 (en) 2001-08-03
NO20001399D0 (no) 2000-03-17
MY116280A (en) 2003-12-31
BR9812088A (pt) 2000-09-26
AR015448A1 (es) 2001-05-02
RU2214824C2 (ru) 2003-10-27
DE69814882T2 (de) 2004-05-19
JP2001516718A (ja) 2001-10-02
TW589183B (en) 2004-06-01
HUP0200602A2 (hu) 2002-07-29
ZA987817B (en) 1999-03-18
SE9703375D0 (sv) 1997-09-18

Similar Documents

Publication Publication Date Title
ATE240733T1 (de) Kombination von 5-ht wiederaufnahme-inhibitoren und h5-ht 1b antagonisten oder partiellen agonisten
NO975244D0 (no) 5-ring-heterocykluser som inhibitorer av leukocyttadhesjon og VLA-4-antagonister
NO975245D0 (no) Heterocykluser som inhibitorer av laukocyttadhesjon og VLA-4-antagonister
DE69831755D1 (de) Optoakustische kontrastmittel und anwendungsverfahren
ID17316A (id) Komposisi aditif untuk pembawa bahan bermanfaat dan komposisi batang yang mengandung aditif tersebut
DE59709342D1 (de) Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE69835020D1 (de) Plasmabrenner und verwendungsverfahren dieses plasmabrenners
DE69704877D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung und prophylaxe der multiplen sclerose
MA26668A1 (fr) ACTIVATEURS DE hPPARy ET hPPARa
DE69632610D1 (de) Zementzusammensetzungen und ihre Verwendung zur Zementierung von Ölbohrlöchern oder ähnlichen
EP1047426A4 (fr) Utilisation du methylnaltrexone et composes afferents a ce compose
DE69430662D1 (de) Zusammensetzungen von fluorkohlenwasserstoffen und kohlenwasserstoffen
ID22650A (id) Penggunaan penghambat-penghambat lipase usus lambung
NO20000268D0 (no) Anvendelse av Lactobacillus for reduksjon av fibrinogen nivå
DK0736525T3 (da) Benzonitriler som 5-HT-agonister og -antagonister
DE69815547D1 (de) Abrasionsbeständige tinenzusammensetzungen und verwendungsverfahren
PT927183E (pt) Inibidores espirociclicos de metaloproteases
EE200000146A (et) Monoamiini oksüdaasi inhibiitori kombinatsioon h5-HT 1B antagonisti või osalise agonistiga
DE69418203D1 (de) Zementiermittel und ihre verwendung
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
FI952458L (fi) Dimetyylibentsofuraanien ja dimetyylibentsopyraanien käyttö 5-HT3-antagonisteina
PT826679E (pt) Compostos de naftilo intermediarios composicoes e metodos de utilizacao
DE69524590D1 (de) Zusammensetzung von 5htida und 5htid antagonisten
IS5408A (is) Samsetning valvísra 5-HT1A mótlyfja og valvíss h5-HT1B mótlyfs eða gerandefnis með hlutaverkun
ID27769A (id) Penggunaan turunan-turunan taksoid baru

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1014985

Country of ref document: EP

REN Ceased due to non-payment of the annual fee